Is Canaccord Positive On Shares of BioMarin Pharm (BMRN)?

May 17, 2018 - By Linda Rogers

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Logo

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.08, from 1.13 in 2017Q3. It is positive, as 37 investors sold BioMarin Pharmaceutical Inc. shares while 112 reduced holdings. 51 funds opened positions while 130 raised stakes. 172.01 million shares or 0.29% more from 171.51 million shares in 2017Q3 were reported.

Dynamic Limited accumulated 0.81% or 26,291 shares. Highland L P holds 0.01% or 2,450 shares in its portfolio. Moreover, Canada Pension Plan Investment Board has 0.02% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 98,249 shares. Barclays Public Ltd Liability Corporation has 0.03% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 355,585 shares. Covington Cap Mgmt stated it has 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Proshare Advsr Limited Liability Corporation reported 0.11% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Eventide Asset Mgmt Limited has 0.35% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). The Missouri-based Scout Invs Incorporated has invested 0.25% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Sivik Global Lc has 2.48% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 75,000 shares. Tarbox Family Office owns 1,020 shares for 0.04% of their portfolio. Cap World Invsts holds 0.03% or 1.45M shares in its portfolio. Valley Natl Advisers, Pennsylvania-based fund reported 17 shares. Prelude Cap Mngmt Ltd Liability Com accumulated 10,236 shares. 99,334 were reported by Great West Life Assurance Can. Elk Creek Prtnrs Limited Liability Company has invested 0.03% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Since December 14, 2017, it had 0 insider purchases, and 21 insider sales for $14.93 million activity. Shares for $801,200 were sold by FUCHS HENRY J. Davis George Eric sold $2.72M worth of stock or 30,000 shares. Ajer Jeffrey Robert also sold $366,475 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares. BIENAIME JEAN JACQUES also sold $836,458 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, April 20. The insider HERON ELAINE J sold $71,116. On Monday, April 23 SPIEGELMAN DANIEL K sold $908,497 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 11,059 shares.

Why Has Canaccord Given BioMarin Pharm (BMRN) a $101.0 Price Target

Canaccord has just issued a Buy rating for BioMarin Pharm (BMRN) shares. The firm initiated coverage on shares of BMRN in an analyst note sent to investors on Wednesday morning. This PT would suggest upside of 13.87 % from the current price of BioMarin Pharm (BMRN).

The stock increased 0.92% or $0.82 during the last trading session, reaching $89.52. About 567,966 shares traded. BioMarin Pharmaceutical Inc. (BMRN) has declined 11.55% since May 17, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.

Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on August, 1. They expect $-0.05 EPS, 0.00 % or $0.00 from last year’s $-0.05 per share. After $-0.08 actual EPS reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -37.50 % EPS growth.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $15.82 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: which released: “BioMarin Cruises While It Waits on Seventh Approval” on April 27, 2018, also with their article: “Andreas Halvorsen Buys Alibaba, United States Steel in 1st Quarter” published on May 15, 2018, published: “BioMarin Pharmaceutical (BMRN) Q1 2018 Results – Earnings Call Transcript” on April 26, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: and their article: “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in …” published on May 15, 2018 as well as‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 16, 2018.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.